B-NHL typically form as malignant lymphoid tumors in the intestines or kidneys. The most common types of b-NHL are small lymphocytic lymphoma and marginal zone lymphoma of mucosa-associated lymphoid tissue. B-NHL is associated with an increasing use of radiation therapy to prevent the disease recurrence, with the disease-free survival, time of relapse and overall survival of patients improved.
A n unknown cause probably exists in 5-20% of patients with lymphoma of B-cell lineage who have an association with an inflammatory bowel disease such as ulcerative colitis or Crohn's disease as evidenced by the occurrence of lymphomas in close family members or in first degree relatives with either of these conditions.
Most lymphomas diagnosed are of B cell type. Around 3,600 cases of marginal zone lymphoma and 11,200 cases of mantle cell lymphomas will be diagnosed in the United States in 2019, an increase from around 800 and 5,700 cases in 2016, respectively. The incidence of marginal zone lymphoma will increase from 2016 levels by 25%, while lymphoma incidence will see a decline by about 10%. The number of cases of mantle cell lymphoma will increase by 30%, and it will decline by 10% from 2016 levels. These diseases are particularly relevant since over 90% of these cancers are curable.
Lymphoma in the bone is most commonly seen in the long bones, is frequently localized at the site, and presents with pain and the development of a mass. Lymphoma can be distinguished from other b-cell malignancies on the basis of its presence in the peripheral blood; therefore, this form of lymphoma is also most often localized to sites without obvious signs of disease. Because bone marrow involvement occurs more frequently with marginal zone lymphoma than with small-cell lymphoma, this entity is also most often localized to the skeleton. B cell marginal zone lymphoma may also present in the intestines.
Most treatments for lymphoma, b-cell, marginal zone include chemotherapy (most commonly cyclophosphamide, or CHOP, and/or rituximab and/or fludarabine and lenalidomide) and most commonly radiotherapy. Other forms of treatment include rituximab monoclonal antibody alone or in combination with a stem-cell transplant, autologous stem-cell transplant, or rituximab monoclonal antibody plus alkylating agents and/or platinum chemotherapy. Most lymphoma, b-cell, marginal zone patients will have the first recurrence of B-cell malignancy, most commonly B-cell lymphoma.
Recent findings indicate that while the rate of cure for a single treatment regimen can be as high as 90%, some patients can have multiple treatments before they progress.
We report a new BCL2 protein mutation in a parent and a daughter with bxPV, with an earlier onset of disease, which in patients with similar clinical presentation might lead to a more aggressive phenotype.
The treatment of relapsed or refractory CD10+ B-cell marginal zone lymphoma with BK-10 resulted in remission in 71% of patients. Mosunetuzumab was better tolerated than the control regimen.
This model represents an important step forward, as it will allow comparison between data from the two studies in this paper. In a recent study, findings, in view of the high incidence of the disease, offer a basis for more in-depth statistical studies.
In most cases, treatment with mosunetuzumab does not prolong survival time from the initial presentation to the initiation of subsequent therapy. Survival time is directly proportional to the time after diagnosis when initiating initial therapy. A treatment strategy to improve survival time is to administer initial therapy sooner after diagnosis and to continue it for longer than it would take on the subsequent treatment courses.
Since the US FDA approved mosunetuzumab for the treatment of relapsed or refractory indolent B-cell malignancies, the results of additional clinical trials investigating its effects in treating B-cell cancers have been encouraging in terms of success in treating patients with refractory/relapsed disease, and for the potential to decrease the use of chemotherapy. Nonetheless, the exact mechanism of action of mosunetuzumab in treating B-cell malignancies has yet to be fully characterized. In addition, further development and clinical trials of mosunetuzumab for treating other cancers are anticipated.
Mosunetuzumab had no clinically significant effects other than infusion-related grade 3 pain. The majority of infusion-related pain was mild. It was transient and usually was well controlled with oral analgesia. Mosunetuzumab had no clinically significant cardiovascular effects.